HK Stock Market Move | KEYMED BIO-B (02162) Falls Over 3% Again; CLSA Says Market Sentiment Weak After Release of Major Clinical Data for CLARITY-Gastric 01

KEYMED BIO-B (02162) fell more than 3% again, down 3.24% as of press time to HK$67.1, with turnover of HK$253 million. On the news front, CLSA's latest research report noted that KEYMED BIO-B closed down 14.4% yesterday, after the company's overseas partner Astrazeneca PLC Sponsored ADR (AZN.US) presented positive sone-ve data at ESMO 2026. The bank attributed the sell-off to weak market sentiment following yesterday's major clinical catalyst. The bank noted that Astrazeneca PLC Sponsored ADR's full analysis of CLARITY-Gastric 01 for sone-ve (CLDN18.2 ADC) at ESMO 2026 was overall encouraging and in line with market expectations; however, a potential concern in the data was that the HR ratio in the second-line intent-to-treat (2L ITT) population was less than ideal. In addition, Astrazeneca PLC Sponsored ADR's management meeting held overnight was also positive, with management reiterating a peak sales opportunity of US$3 billion to US$5 billion for the asset in second- and third-line CLDN18.2-positive gastric cancer indications.